Literature DB >> 15221268

Percutaneous placement of peritoneal port-catheter in oncologic patients.

Franco Orsi1, Paolo Della Vigna, Silvia Penco, Guido Bonomo, Elena Lovati, Massimo Bellomi.   

Abstract

The aim of this paper is to describe the technique of percutaneous ultrasound (US)-guided placement of a peritoneal port-catheter in an interventional radiological setting. Nineteen patients with peritoneal carcinomatosis were selected for intraperitoneal port-catheter placement in order to perform intracavitary receptor-immuno- or radio-immunotherapy with Ytrium-90. All the procedures were performed percutaneously under US and fluoro guidance; the insertion site for catheters was chosen according to abdominal conditions and US findings: all devices were implanted at the lower abdominal quadrants. All patients were followed up with CT and US according to the therapy protocol. The procedure was successfully completed in 15/19 patients, in 4 being contraindicated by peritoneal adhesions. No procedure-related complications and device occlusions during therapy were observed; one catheter displaced 7 months later the placement. In our experience, this procedure was feasible, reliable and easy to perform, allowing the correct administration of the planned intracavitary therapy. Peritoneal adhesions are the main limitation of peritoneal port placement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221268     DOI: 10.1007/s00330-004-2367-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  13 in total

1.  Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.

Authors:  E Topuz; Y Salihoglu; A Aydiner; P Saip; F Tas; T Sozen; S Berkman; E Bengisu
Journal:  J Surg Oncol       Date:  2000-07       Impact factor: 3.454

Review 2.  Experimental and clinical status of intraperitoneal chemotherapy.

Authors:  G Los; J G McVie
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

3.  Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis.

Authors:  P Braly; J Doroshow; S Hoff
Journal:  Gynecol Oncol       Date:  1986-11       Impact factor: 5.482

Review 4.  Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.

Authors:  M Markman
Journal:  Cancer Treat Rev       Date:  1986-12       Impact factor: 12.111

5.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

6.  Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin.

Authors:  G Paganelli; C Belloni; P Magnani; F Zito; A Pasini; I Sassi; M Meroni; M Mariani; M Vignali; A G Siccardi
Journal:  Eur J Nucl Med       Date:  1992

7.  [Implantable catheter systems. Experience with 205 patients].

Authors:  U Laffer; M Dürig; H R Bloch; M Zuber; H R Stoll
Journal:  Dtsch Med Wochenschr       Date:  1989-04-28       Impact factor: 0.628

8.  Intraperitoneal therapy administered through a Groshong catheter.

Authors:  S E Waggoner; J Johnson; J Barter; W Barnes
Journal:  Gynecol Oncol       Date:  1994-06       Impact factor: 5.482

9.  Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.

Authors:  H Malmström; J Carstensen; E Simonsen
Journal:  Gynecol Oncol       Date:  1994-07       Impact factor: 5.482

10.  Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system.

Authors:  L Almadrones; C Yerys
Journal:  Oncol Nurs Forum       Date:  1990 Jan-Feb       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.